St. Jude Family of Websites

Explore our cutting edge research, world-class patient care, career opportunities and more.

St. Jude Children's Research Hospital Home

St. Jude Children's Research Hospital
St. Jude Care & Treatment

Menu

Close

Open, not recruiting

HAPNK1: Blood and Marrow Transplant (BMT) for Children with Leukemia/Lymphoma

About this study

Hematologic cancers are cancers of the blood and lymphatic system. These include leukemias and lymphomas. Generally, patients with blood cancers are treated successfully with strong anti-cancer medicines, also known as chemotherapy. However, some blood cancers can be hard to treat. They may come back after treatment or may respond poorly to treatment.

This clinical trial will study allogeneic hematopoietic cell transplant (sometimes called bone marrow transplant) as a treatment for these difficult cancers. Allogeneic transplantation uses hematopoietic progenitor (blood making) cells that are obtained from someone other than the patient. That person is called the donor. These cells are given to the patient in a procedure called infusion.

Standard transplants begin with radiation and/or chemotherapy to damage or kill your bone marrow. Bone marrow is mostly located in the large bones of the body like the hips and leg bones. Killing or damaging the bone marrow makes room within the bones for cells donated by someone else. The body needs these donor progenitor (blood making) cells to restore and rebuild bone marrow. The donor cells travel through the patient’s blood to the bone marrow space and begin to grow and make new blood cells. Immune system cells from the donor are also infused. These immune cells can sometimes attack the cancer cells and prevent them from coming back.

Purpose of this clinical trial

The main purpose of this study is to see how well this type of transplant works in children and adolescents with certain kinds of blood cancers that have come back after treatment or not responded well to treatment. Researchers want to know the good and bad effects of the transplant. They also want to learn more about how the body’s immune system responds to the transplant.

Eligibility overview

  • 21 years and younger
  • Does not have a suitable human leukocyte antigen (HLA)-matched sibling donor or volunteer HLA-matched unrelated donor or is not a candidate due to refractory disease
  • Has a suitable single haplotype-matched family member donor
  • High-risk hematologic malignancy, including certain diagnoses of:
    • Acute lymphoblastic leukemia (ALL)
    • Acute myeloid leukemia (AML)
    • Chronic myelogenous leukemia (CML)
    • Myelodysplastic syndrome (MDS)
    • Hodgkin lymphoma
    • Non-Hodgkin lymphoma

Request a referralLearn about clinical research

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.

Overview

Full title:

Haploidentical Donor Hematopoietic Progenitor Cell and Natural Killer Cell Transplantation with a TLI-Based Conditioning Regimen in Patients with Hematologic Malignancies

Study goal:

The main purpose of this study is to see how well this type of transplant works in children and adolescents with certain kinds of blood cancers that have come back after treatment or not responded well to treatment.

Diagnosis:

Leukemia, lymphoma

Age:

21 years and younger

Clinical trials categories:

Hodgkin Lymphoma Acute Myeloid Leukemia (AML) Childhood Cancer Lymphoma Leukemia Myelodysplastic Syndromes Non-Hodgkin Lymphoma Acute Lymphoblastic Leukemia (ALL)

For physicians and researchers

Patients accepted to St. Jude must be referred by a physician or other qualified medical professional. Learn how St. Jude can partner with you to care for your patient.

 

Learn more